Rebeccamycin
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.
For research use only. We do not sell to patients.
- CAS No.: 93908-02-2
- Formula: C27H21Cl2N3O7
- Molecular Weight:570.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Topoisomerase I |
Traditional Cytotoxic Agents |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
|
[PMID: 11882002] |
| B16 | IC50 |
0.48 μM
Compound: 1
|
Inhibition of murine B16 Melanoma cell proliferation
Inhibition of murine B16 Melanoma cell proliferation
|
[PMID: 9341921] |
| B16 | IC50 |
0.48 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against murine B16 melanoma cells
Antiproliferative activity measured against murine B16 melanoma cells
|
[PMID: 9572888] |
| B16 | IC50 |
0.48 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity against B16 mouse melanoma cells
Antiproliferative activity against B16 mouse melanoma cells
|
[PMID: 8893841] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1
|
The cytotoxicity was evaluated in in HIV -I Lai infected CEM-SS cells.
The cytotoxicity was evaluated in in HIV -I Lai infected CEM-SS cells.
|
[PMID: 10346933] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against HIV-1 Lai infected CEM-SS cells
Cytotoxicity against HIV-1 Lai infected CEM-SS cells
|
[PMID: 10052965] |
| CEM-SS | CC50 |
1.05 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxic concentration is tested against CEM-SS cells
Cytotoxic concentration is tested against CEM-SS cells
|
[PMID: 9572888] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1 (Rebeccamycin)
|
Anti-HIV-1 activity in CEM-SS cells was measured by the quantification of the reverse transcriptase activity, associated with the virus particles released from HIV-1 infected cells in the culture medium.
Anti-HIV-1 activity in CEM-SS cells was measured by the quantification of the reverse transcriptase activity, associated with the virus particles released from HIV-1 infected cells in the culture medium.
|
[PMID: 10052965] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1
|
Compound was tested for anti-HIV activity in HIV -I Lai infected CEM-SS cells.
Compound was tested for anti-HIV activity in HIV -I Lai infected CEM-SS cells.
|
[PMID: 10346933] |
| CEM-SS | IC50 |
0.52 μM
Compound: 1 (Rebeccamycin)
|
Inhibitory concentration is tested in HIV-1 Lai-infected CEM-SS cells
Inhibitory concentration is tested in HIV-1 Lai-infected CEM-SS cells
|
[PMID: 9572888] |
| HT-29 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line.
Antiproliferative activity in vitro against HT-29 (human colon carcinoma) cell line.
|
[PMID: 11882002] |
| HT-29 | IC50 |
0.3 μM
Compound: Rebeccamycin
|
In vitro antiproliferative activity against human colon carcinoma HT-29 cells
In vitro antiproliferative activity against human colon carcinoma HT-29 cells
|
[PMID: 15743184] |
| K562 | IC50 |
0.2 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity in vitro against K-562 (human leukemia) cell line.
Antiproliferative activity in vitro against K-562 (human leukemia) cell line.
|
[PMID: 11882002] |
| K562 | IC50 |
4 μM
Compound: Reb
|
Anticancer activity against human K562 cells
Anticancer activity against human K562 cells
|
[PMID: 18653350] |
| K562 | IC50 |
6 μM
Compound: Rebeccamycin
|
Inhibitory concentration against K5662 leukemia cell line in MTS assay
Inhibitory concentration against K5662 leukemia cell line in MTS assay
|
[PMID: 15801850] |
| L1210 | IC50 |
0.1 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line.
Antiproliferative activity tested in vitro against L1210 (murine leukemia) cell line.
|
[PMID: 11882002] |
| L1210 | IC50 |
0.14 μM
Compound: Rebeccamycin
|
Cytotoxicity activity against mouse L1210 cells by MTT assay
Cytotoxicity activity against mouse L1210 cells by MTT assay
|
[PMID: 20566289] |
| L1210 | IC50 |
0.14 μM
Compound: Rebeccamycin
|
In vitro antiproliferative activity against murine leukemia L1210 cells
In vitro antiproliferative activity against murine leukemia L1210 cells
|
[PMID: 15743184] |
| P388 | IC50 |
0.3 μM
Compound: 1 ; Rebeccamycin
|
Antiproliferative activity against P388 Murine Leukemia cells
Antiproliferative activity against P388 Murine Leukemia cells
|
[PMID: 8893841] |
| P388 | IC50 |
0.5 μM
Compound: 1
|
Inhibition of P388 murine leukemia cell proliferation
Inhibition of P388 murine leukemia cell proliferation
|
[PMID: 9341921] |
| P388 | IC50 |
1.22 μM
Compound: 1
|
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
In vitro inhibitory concentration against murine P388 leukemia cell proliferation
|
[PMID: 10346933] |
| P388 | IC50 |
1.22 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against P388 leukemia cells
Cytotoxicity against P388 leukemia cells
|
[PMID: 10052965] |
| P388 | IC50 |
1.22 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against P388 Leukemia cells
Antiproliferative activity measured against P388 Leukemia cells
|
[PMID: 9572888] |
| P388 | IC50 |
10.5 μM
Compound: 1 (Rebeccamycin)
|
Cytotoxicity against P388/CPT5 leukemia cells.
Cytotoxicity against P388/CPT5 leukemia cells.
|
[PMID: 10052965] |
| P388CPT5 | IC50 |
10.5 μM
Compound: 1
|
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
In vitro inhibitory concentration against murine P388CPT5 leukemia cell proliferation
|
[PMID: 10346933] |
| P388CPT5 | IC50 |
10.5 μM
Compound: 1 (Rebeccamycin)
|
Antiproliferative activity measured against P388CPT5 cells resistant to Topoisomerase I inhibitor Camptothecin
Antiproliferative activity measured against P388CPT5 cells resistant to Topoisomerase I inhibitor Camptothecin
|
[PMID: 9572888] |
| SW-620 | IC50 |
4 μM
Compound: Reb
|
Anticancer activity against human SW620 cells
Anticancer activity against human SW620 cells
|
[PMID: 18653350] |
| SW-620 | IC50 |
4 μM
Compound: Rebeccamycin
|
Inhibitory concentration against SW620 colorectal carcinoma cell line in MTS assay
Inhibitory concentration against SW620 colorectal carcinoma cell line in MTS assay
|
[PMID: 15801850] |
Rebeccamycin is an antitumor antibiotic produced by the actinomycete Saccharotrix aerocolonigenes with activity against several human tumor cell lines, including A549 (lung adenocarcinoma), HCT-116 (colon carcinoma), and KB (nasopharyngeal carcinoma) [1].
Rebeccamycin shows antibacterial activity against several Gram-positive bacteria, including Staphylococcus aureus and Streptococcus faecalis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CDF1 mice (B16 melanoma, L1210 leukemia)[2]
-
Dosage:2, 4, 8, 16, 32, 64, 128, 256 mg/kg
-
Administration:I.p.; daily for 9 days
-
Result:Prolongation of survival of the mice at dose levels ranging from 8 to 256 mg/kg.
Chemical Information
-
CAS No. 93908-02-2
-
Molecular Weight 570.38
-
Formula C27H21Cl2N3O7
-
SMILES
O=C(N1)C(C2=C3N([C@@H]([C@@H]([C@@H](O)[C@@H]4OC)O)O[C@@H]4CO)C5=C2C=CC=C5Cl)=C(C(C6=CC=C7)=C3NC6=C7Cl)C1=O
-
Structure Classification
-
Initial Source
the mycelium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Merchant J, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002 Jul;8(7):2193-201. [Content Brief]
[2]. Bush JA, et al. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo). 1987 May;40(5):668-78. [Content Brief]
[3]. Sánchez C, et al. The biosynthetic gene cluster for the antitumor rebeccamycin: characterization and generation of indolocarbazole derivatives. Chem Biol. 2002 Apr;9(4):519-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)